KalVista Pharmaceuticals, Inc. (KALV) Debt by Year
KalVista Pharmaceuticals, Inc. held $131.6M in cash and equivalents at the end of fiscal year 2025, and long-term debt is not reported for that period. The table below carries 12 fiscal years, from 2013 to 2025, and the quarters KalVista Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
KALV Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-KT/A | FY2410-Q | FY2310-KT/A | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1410-K | FY1310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $131.6M+314.0% | $31.8M-43.5% | $56.2M+83.0% | $30.7M-39.3% | $50.6M+220.4% | $15.8M-50.7% | $32.0M-37.3% | $51.1M+65.0% | $30.9M-36.1% | $48.5M | $3.9M-60.2% | $9.8M |
KALV Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $172.2M | $172.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $213.8M+62.4% | $229.3M+25.8% | $243.5M+485.6% | $124.3M+290.3% | $131.6M+314.0% | $182.3M+690.8% | $41.6M-27.9% | $31.8M-35.5% | $31.8M-43.5% | $23.1M-72.9% | $57.7M+49.5% | $49.4M+30.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More KalVista Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was KalVista Pharmaceuticals, Inc.'s long-term debt in fiscal year 2025?
KalVista Pharmaceuticals, Inc. held $131.6M in cash and equivalents at the end of fiscal year 2025, and long-term debt is not reported for that period.
What was KalVista Pharmaceuticals, Inc.'s long-term debt in the most recent quarter?
KalVista Pharmaceuticals, Inc. (KALV) reported $172.2M in long-term debt in Q4 2026.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what KalVista Pharmaceuticals, Inc. (KALV) reported on that line in every period on record.